H.C. Wainwright maintains Buy on Immunovant, $51 price target

On Monday, H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst targets range from $41 to $58, with a strong consensus Buy rating. The firm’s analyst, Douglas Tsao, highlighted upcoming clinical trial results that are anticipated to provide further evidence for the therapeutic approach of Immunovant’s batoclimab in treating autoimmune conditions.

Immunovant’s batoclimab is currently being evaluated in clinical trials for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The top-line data from these trials are expected by the end of March. The results are set to clarify the clinical benefits of deeper IgG reduction—a concept that has been debated but not conclusively proven in clinical practice. With a market capitalization of $3.47 billion and a robust current ratio of 6.04, InvestingPro analysis shows the company maintains strong liquidity to support its clinical programs.

The analyst noted that Vyvgart, another treatment for MG, showed best-in-class efficacy in a Phase 3 study with the lowest IgG reduction among competitors. However, recent findings suggest that IgG reduction alone might not be adequate to suppress the immune response associated with autoantibodies in MG.

Despite these considerations, Tsao mentioned that the medical community would welcome new treatment options that offer different dosing forms and schedules. Immunovant is not planning to continue the development of batoclimab but will focus on advancing IMVT-1402 as their lead asset.

Further, Immunovant is preparing to release additional data from a proof-of-concept study of batoclimab in Graves’ disease (GD), including information on 6-month treatment-free remission, which is expected to be available in the summer of 2025. The reaffirmation of the Buy rating and the $51 price target reflects confidence in the company’s pipeline and potential for growth. Trading near its 52-week low of $19.86, InvestingPro subscribers can access detailed financial health metrics and 8 additional ProTips to better evaluate this clinical-stage biotech company’s investment potential.

In other recent news, Immunovant has registered shares for resale by certain stockholders. The filing indicates that up to 5,654,990 shares of Immunovant’s common stock are now registered for resale, acquired by the stockholders through a private placement financing. This move allows the identified stockholders to resell their shares in the public market, providing them with the option to do so.

On the analysis front, Guggenheim Securities has raised its price target for Immunovant from $44.00 to $46.00, maintaining a Buy rating on the stock. The firm is anticipating several significant developments from the company’s batoclimab program, expected to deliver results in 2025.

Furthermore, Piper Sandler, a leading investment bank, has identified Immunovant as one of the companies with the most direct catalysts within the next 12 months. The company is expected to present at least three significant data catalysts. These recent developments indicate a period of potential growth and change for Immunovant.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.